Aubex Therapeutics Launches to Revolutionize Cancer Treatment with Novel Compounds directed toward the Tumor Microenvironment
April 23 2024 - 10:32AM
Business Wire
Aubex Therapeutics Inc., a pioneering biotechnology firm, today
announced its official launch, heralding a new era in the battle
against cancer. Under the guidance of Board Member and Interim CEO,
Jeffrey Glazer, Aubex’s initial program is focused on novel
compounds aimed at transforming the treatment of solid tumor
malignancies through a unique approach to modifying the tumor
microenvironment (TME).
Aubex’s R&D program shows promise, particularly in cancers
where fibrosis drives progression, such as HER2+ and
triple-negative (TN) breast cancers, pancreatic cancer, esophageal
squamous cell carcinoma (SCC), colon cancer, and non-small cell
lung cancer. These solid tumors are notable for their pronounced
fibrotic response, which impedes effective immune responses.
Jeffrey A. Glazer expressed his excitement about the company's
mission, stating, "Aubex Therapeutics is thrilled to launch with a
unique R&D program addressing the TME. This innovative program
demonstrates promising early activity in altering the tumor
microenvironment, marking a significant milestone in
immuno-oncology. We are eager to lead the way in developing
therapies that hold the potential to dramatically improve outcomes
for cancer patients by reducing fibrosis and boosting a patient’s
immune response."
The launch of Aubex Therapeutics marks a pivotal moment in the
ongoing effort to develop more effective cancer treatments. With a
focus on achieving groundbreaking progress in the therapy of solid
tumors, Aubex is dedicated to improving patient outcomes through
innovative research.
About Aubex Therapeutics Inc.
Headquartered in San Diego, CA, Aubex Therapeutics, Inc. is a
biotechnology leader dedicated to advancing oncology treatment.
Guided by industry veterans, Aubex focuses on novel therapies that
improve the dynamics of the tumor microenvironment. Committed to
innovation, patient well-being, and ethical practices, the company
strives to enhance treatment efficacy and patient quality of
life.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240423475058/en/
Eliza Thornhill Email: info@aubextherapeutics